Research Analysts’ Weekly Ratings Changes for Flexion Therapeutics (FLXN)

Flexion Therapeutics (NASDAQ: FLXN) recently received a number of ratings updates from brokerages and research firms:

  • 9/11/2017 – Flexion Therapeutics was given a new $44.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 9/1/2017 – Flexion Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/28/2017 – Flexion Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
  • 8/24/2017 – Flexion Therapeutics is now covered by analysts at Northland Securities. They set an “outperform” rating and a $40.00 price target on the stock.
  • 8/22/2017 – Flexion Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “
  • 8/11/2017 – Flexion Therapeutics had its “buy” rating reaffirmed by analysts at BMO Capital Markets.
  • 8/10/2017 – Flexion Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $44.00 price target on the stock.
  • 8/10/2017 – Flexion Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock, up previously from $34.00.

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) traded down 3.29% during trading on Tuesday, hitting $23.21. 384,757 shares of the company’s stock were exchanged. Flexion Therapeutics, Inc. has a one year low of $15.44 and a one year high of $29.41. The stock’s market cap is $740.52 million. The firm has a 50-day moving average price of $23.29 and a 200-day moving average price of $21.92.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities research analysts expect that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current fiscal year.

In other news, Director Mark Stejbach bought 1,580 shares of Flexion Therapeutics stock in a transaction on Friday, June 16th. The shares were bought at an average cost of $17.02 per share, for a total transaction of $26,891.60. The transaction was disclosed in a filing with the SEC, which is available at this link. 15.98% of the stock is currently owned by corporate insiders.

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.